Kathleen M. Woods Ignatoski

Dr. Kathleen M. Woods Ignatoski

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SISuthinee Ithimakin
Suthinee Ithimakin
KDKathleen C. Day
Kathleen C. Day
FMFayaz Malik
Fayaz Malik
QZQin Zen
Qin Zen
SDScott J. Dawsey
Scott J. Dawsey
MWMax Wicha
Max Wicha
Although current breast cancer treatment guidelines limit the use of HER2-blocking agents to tumors with HER2 gene amplification, recent retrospective analyses suggest that a wider group of patients may benefit from this therapy. Using breast cancer cell lines, mouse xenograft models and matched human primary and metastatic tissues, we show that HER2 is selectively expressed in and regulates self-renewal of the cancer stem cell (CSC) population in estrogen receptor-positive (ER+), HER2− luminal breast cancers. Although trastuzumab had no effects on the growth of established luminal breast cancer mouse xenografts, administration after tumor inoculation blocked subsequent tumor growth. HER2 expression is increased in luminal tumors grown in mouse bone xenografts, as well as in bone metastases from patients with breast cancer as compared with matched primary tumors. Furthermore, this increase in HER2 protein expression was not due to gene amplification but rather was mediated by receptor activator of NF-κB (RANK)-ligand in the bone microenvironment. These studies suggest that the clinical efficacy of adjuvant trastuzumab may relate to the ability of this agent to target the CSC population in a process that does not require HER2 gene amplification. Furthermore, these studies support a CSC model in which maximal clinical benefit is achieved when CSC targeting agents are administered in the adjuvant setting. Cancer Res; 73(5); 1635–46. ©2012 AACR.

1 April 2015 in Surgery
Verified
Journal Article
Closed access
MRMatthew W. Ralls
Matthew W. Ralls
FDFarokh Demehri
Farokh Demehri
YFYongjia Feng
Yongjia Feng
KIKathleen M. Woods Ignatoski
Kathleen M. Woods Ignatoski
DTDaniel H. Teitelbaum
Daniel H. Teitelbaum

1 January 2003
Verified
Journal Article
Closed access
CKChandan Kumar-Sinha
Chandan Kumar-Sinha
KIKathleen M. Woods Ignatoski
Kathleen M. Woods Ignatoski
MLMarc Lippman
Marc Lippman
SEStephen P Ethier
Stephen P Ethier
ACArul M Chinnaiyan
Arul M Chinnaiyan

19 April 2012 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
BMBarbra S. Miller
Barbra S. Miller
KIKathleen M. Woods Ignatoski
Kathleen M. Woods Ignatoski
SDStephanie Daignault
Stephanie Daignault
CLCeit Lindland
Ceit Lindland
MDMegan Doherty
Megan Doherty
TGThe University of Michigan Analytical Morphomics Group
The University of Michigan Analytical Morphomics Group

1 September 2009 in Stem Cells and Development
Verified
Journal Article
Closed access
EBEve L. Bingham
Eve L. Bingham
SCShih-Ping Cheng
Shih-Ping Cheng
KIKathleen M. Woods Ignatoski
Kathleen M. Woods Ignatoski
GDGerard M. Doherty
Gerard M. Doherty
Iatrogenic hypoparathyroidism is the most common complication of cervical endocrine surgery. Current management is limited and palliative. As the molecular steps in parathyroid development have been defined, they may be replicable in vitro, with a goal of cellular replacement therapy. Human embryonic stem cell (hESC) lines were investigated as a model for parathyroid regeneration in vitro. BG01 was selected as a model based on expression of genes of interest in embryoid bodies (EBs). Established strategies for mouse embryonic stem cell differentiation into definitive endoderm were modified and extended to maximize the expression of definitive markers of parathyroid development. The optimal approach included the use of Activin A at 100 ng/mL with BG01 cells grown on murine embryonic fibroblasts for 5 days under conditions of increasing serum concentration. After 5 days, the cells were allowed to mature further in tissue culture without murine fibroblasts but with continuous Activin A. Our strategy produced differentiated cell cultures that expressed intermediate markers of endoderm and parathyroid development (CXCR4, EYA1, Six1, and Pax1), as well as markers of committed parathyroid precursors or developed parathyroid glands (glial cell missing-2 [Gcm2], CCL21, calcium sensing receptor [CaSR], and parathyroid hormone [PTH]). We further characterized the cells by testing conditioned medium from various time points in our differentiation scheme for the presence of PTH. We found that by keeping the cells in culture 2 weeks after the withdrawal of Activin A, the cells were able to produce PTH. Further in vivo work will be needed to demonstrate proper functionality of the cells developed in this way.

1 March 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
STStephanie Tseng-Rogenski
Stephanie Tseng-Rogenski
JGJason Gee
Jason Gee
KIKathleen M. Woods Ignatoski
Kathleen M. Woods Ignatoski
LKLakshmi P. Kunju
Lakshmi P. Kunju
ABAmanda Bucheit
Amanda Bucheit
MLMonica Liebert
Monica Liebert